TB Research

HIV Remains a Risk Factor for Unfavorable Tuberculosis Treatment Outcomes in the Era of Universal Access to Antiretroviral Therapy in Botswana.

Azadeh Baniasad, Siheng Chao, James A Nguyen, Emily Tian, Chawanga Modongo, Volodymyr M Minin, Jessalyn N Sebastian, Sanghyuk S Shin

medRxiv : the preprint server for health sciences · 2025-11

Abstract

Botswana implemented its universal "Treat All" antiretroviral therapy (ART) policy in 2016, expanding treatment eligibility to all people living with HIV (PLHIV). HIV has been known to be a leading risk factor for tuberculosis (TB) and poor TB treatment outcomes. The primary goal of this study is to assess whether HIV infection and HIV-associated immunosuppression remain risk factors for unfavorable TB treatment outcomes in the Post-Treat All era. We analyzed 636 TB patients treated in Gaborone (2017-2023), of whom 54.4% were HIV-positive. Unfavorable outcomes (death, failure, or loss to follow-up) occurred in 19.7% of HIV-positive and 8.5% of HIV-negative patients. We used logistic regression to estimate unadjusted and covariate-adjusted associations between TB treatment outcome and HIV status and between TB treatment outcome and CD4+ T-cell count. HIV-positive patients had 2.5-fold higher odds of unfavorable outcomes compared with HIV-negative patients [adjusted OR: 2.51, 95% CI: (1.48, 4.38)], controlling for age, sex, TB history, distance to clinic, substance use, and occupational status. PLHIV with CD4+ T-cell <was associated with approximately three-fold higher odds of unfavorable outcomes compared with HIV-negative participants [OR: 3.12, 95% CI: (1.65, 5.97)]. The secondary goal was to test whether the HIV effect changed following Treat All implementation. We combined the data from 2017-2023 with a Pre-Treat All cohort (2012-2016, n= 233, HIV prevalence 60.8%) and fit a frequentist logistic regression and Bayesian mixed-effects models with an interaction term that allows treatment era (Pre- vs. Post-Treat All) to modify the effect of HIV on TB treatment outcome. The estimated change in the HIV effect was uncertain [relative OR: 0.41; 95% CI: (0.11, 1.55)]. Combining the two Botswana data sets with 12 Pre- and Post-Treat All studies from neighboring Ethiopia showed that the pooled effect of HIV infection on unfavorable TB outcome has increased in the Post-Treat All period [relative OR: 2.39; 95% BCI: (1.36, 3.34)].